Our business

Pioneering research

Aptahem AB is a publicly listed biotechnology company with a business model focused on preclinical and clinical development of aptamer-based treatment for severe, life-threatening  conditions in which coagulation and inflammation are combined in the disease process. Aptahem’s business is based on technology developed from aptamer research at Lund University in cooperation with Karolinska Institutet and The Swedish Institute for Communicable Disease Control (now The Public Health Agency of Sweden). This cooperation led to the development of a new class of synthetic biomolecules, so-called aptamers, which have negligible side effects. Using these aptamers, researchers identified potential capabilities of a malaria model in the brain to dissolve blood clots in cases where the parasite forms blood coagulants to survive. For human patients, this would lead to clots and eventually a fatal stroke.

Aptahem’s current Chief Scientific Officer (CSO) investigated this technology and developed it to include anticoagulant indications. In this way, commercial development began and eventually led to the establishment of Aptahem. Under the leadership of its CSO, Aptahem’s development team discovered a series of positive characteristics among the company’s lead drug candidate, including the strong anti-inflammatory capabilities. Apta-1, Aptahem’s leading drug candidate, is being developed as an emergency drug designed to prevent the damage of organs and tissues that leads to,  among other factors, the high mortality rates in sepsis patients. With an updated development plan, the company intends to take Apta-1 to clinical trials in humans in a clinically exposed area where effective treatment is not currently available. The company’s shares are traded under the APTA Stock name on Spotlight Stock Market (former AktieTorget) since 17 April 2015.




  • Signed an agreement with the CDMO company Recipharm to develop the pharmaceutical formulation of drug candidate Apta-1 for the future phase 1 study.
  • Announced positive final results from the explorative sepsis study with non-human primates, the NHP study. The new preclinical results continue to strengthen Apta-1 as a multi-target drug candidate as potential treatment for sepsis. The finalized vast study report adds to further in-depth understanding about Apta-1’s mechanism of actions and opens for new potential patent opportunities.
  • Apta-1 results were for the first time presented at a scientific conference for intensive care.
  • Signed an agreement with LGC Group, a GMP (Good Manufacturing Practice) certified contract manufacturer.
  • A pilot study using a CLP model showed good effect of Apta-1 in a sepsis-like condition.
  • Aptahem’s patent application for patent family 2 was made publicly available.


  • Extended explorative sepsis study showed very good effect in Apta-1 treated primates
  • A strategic collaboration was initiated with Seattle Children’s Research Institute to explore the underlying mechanisms in their new aptamer-based treatment for acute and chronick inflammatory conditions, including sepsis
  • Safety and toxicology studies for Apta-1 starts
  • Scale-up process for an efficient larger-scale manufacture of Apta-1 finalized
  • The scientific advisory board strengthened with internationally recognised and highly qualified experts in advancement of clinical studies


  • Established a scientific advisory board that supports Aptahem’s development team on strategic and clinical issues.
  • The company’s clinical development strategy and, consequently, its timetable and plans are continuously updated to maximize efforts of reaching communicated milestones and optimising the company’s attractiveness for potential partners and licensees.
  • Entered a GMP production agreement with BioSpring concerning the production of Aptahem’s drug candidate.
  • Announced a positive outcome from pre-clinical animal studies conducted together with Hooke Laboratories in the US. Apta-1 was assessed in a clinically relevant model for sepsis and indicated improved survival with recovered and increased blood circulation among trial animals when administered intravenously.
  • Presented a new development plan for Apta-1 in which its technical characteristics are expected to reach their greatest commercial potential and synergies when treating intensive-care sepsis patients.
  • Submitted a new patent application on recent results of Apta-1’s applications and therapeutic use.


  • Pre-clinical trials show that Apta-1 inhibits several inflammatory factors while simultaneously providing a strong stimulatory effect on certain parts of the body’s own anti-inflammatory response mechanisms.
  • Pre-clinical trials have demonstrated that Apta-1 effectively inhibits the occurrence of blood clots without an increase in bleeding.
  • Studies indicate that Apta-1 has an extremely high safety margin. The safe dose is at least 50 times higher than the proposed restated therapeutic dose in humans.


  • In-vivo and in-vitro trials show that Apta-1 does not result in bleeding at higher doses compared to market-leading products.


  • Founding of the company.


  • Researchers Tina Persson and Johan Lindh, experts in aptamer technology and parasite immunology, respectively, discovered intriguing links between their areas of specialisation. A co-operation began that led to the development of a new class of chemically derived biomolecules, know as aptamers. With these aptamers, the researchers saw potential new inhibitory and dissolving functions on the malaria parasite’s (in the brain) ability to form so-called rosettes. These rosettes clump together and then clog the capillaries, which can cause a blood clot.